A previous study revealed that OS was 2.8 years for low counts of CD19+ B cells (<125 cells/mL), whereas the OS for the high-CD19+ B cell count group (> 125 cells/mL) was 4.0 years in newly diagnosed MM patients (19). The gene discussed is CD19; the disease is Miyoshi myopathy.